onr:"swepub:oai:DiVA.org:liu-25374"
Search: onr:"swepub:oai:DiVA.org:liu-25374" > Chemotherapy of sof...
- 1 of 1
- Previous record
- Next record
- To hitlist
- Wall, Najme,1963-Östergötlands Läns Landsting,Linköpings universitet,Hälsouniversitetet,Onkologi,Onkologiska kliniken US (author)
Chemotherapy of soft tissue sarcoma : A clinical evaluation of treatment over ten years
- Article/chapterEnglish2003
Publisher, publication year, extent ...
- 2009-07-08
- Informa UK Limited,2003
- printrdacarrier
Numbers
- LIBRIS-ID:oai:DiVA.org:liu-25374
- https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-25374URI
- https://doi.org/10.1080/0891060310002249DOI
Supplementary language notes
- Language:English
- Summary in:English
Part of subdatabase
- SwePubSwePub
Classification
Notes
- The aim of the study was to evaluate the effect of palliative chemotherapy on soft tissue sarcomas given outside controlled trials. Therapy and response rates of 77 patients with non-resectable sarcoma treated with different regimens between 1991 and 2000 were reviewed. Thirty-six patients were treated with first-line chemotherapy comprising cyclophosphamide+vincristine+doxorubicin+dacarbazine (CYVADIC), with a response rate of 28% (median response duration 5.5 months). Etoposide and ifosfamide (IVP, or VIG, which also includes granulocyte colony-stimulating factor (G-CSF)) were used in the treatment of 18 patients. The response rate was 22% (median response duration 4.5 months), Nineteen patients were treated with doxorubicin+ifosfamide and one patient responded. Four patients received other first-line treatments. Thirty-eight patients were given second-line chemotherapy and 4 (10%) patients responded. Thirteen patients were given third-line treatment and 5 patients received fourth-line treatment, but without any response. Disease progression was the dominant reason for discontinuation of therapy. The response rate in the present study was lower than the best published results, probably due to the fact that our soft tissue sarcoma patient material was unselected. Treatment with CYVADIC yields at least as high a response rate as the more recently described doxorubicin+ifosfamide combination, but third- and fourth-line therapy is not beneficial. Clinical trials with more active drugs are needed, as are more predictive and prognostic tests and a better selection of patient groups suited for different treatment options for soft tissue sarcomas.
Subject headings and genre
- MEDICINE
- MEDICIN
Added entries (persons, corporate bodies, meetings, titles ...)
- Starkhammar, Hans,1948-Östergötlands Läns Landsting,Linköpings universitet,Hälsouniversitetet,Onkologi,Onkologiska kliniken US(Swepub:liu)hanst87 (author)
- Linköpings universitetHälsouniversitetet (creator_code:org_t)
Related titles
- In:Acta Oncologica: Informa UK Limited42:1, s. 55-610284-186X1651-226X
Internet link
Find in a library
- Acta Oncologica (Search for host publication in LIBRIS)
To the university's database
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Wall, Najme, 196 ...
- Starkhammar, Han ...
- Articles in the publication
- Acta Oncologica
- By the university
- Linköping University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
